Current status of liver diseases in Korea: hepatitis B.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chae H.B. | - |
dc.contributor.author | Kim J.H. | - |
dc.contributor.author | Kim J.K. | - |
dc.contributor.author | Yim H.J. | - |
dc.date.available | 2020-11-03T09:45:25Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1738-222X | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/16569 | - |
dc.description.abstract | Hepatitis B virus (HBV) infection is the one of the most common causes of the liver diseases in Korea. Since the discovery of Australia antigen (hepatitis associated antigen, or HBsAg later), hepatitis associated antigen was tested widely. HBsAg was detected in 6.6-8.6% in 1980's. Later, it decreased to 5.7% in 1990's. Remarkably, seropositivity of the children deceased to 0.2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was reported to be 4.25%. Treatment of chronic hepatitis B was initiated after the introduction of interferon alpha. Lamivudine opened a new era of oral antiviral agent, and it has been widely used in Korea since 1999. Adefovir was proven to have a good efficacy for lamivudine-resistant chronic hepatitis B. Newer potent antiviral agents such as entecavir, clevudine, and telbivudine are available currently. Further studies are warranted for understanding factors influencing natural history, improving treatment outcomes, and overcoming vaccine non-response. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Current status of liver diseases in Korea: hepatitis B. | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/kjhep.2009.15.S6.S13 | - |
dc.identifier.scopusid | 2-s2.0-77952294655 | - |
dc.identifier.bibliographicCitation | The Korean journal of hepatology, v.15 Suppl 6, pp S13 - 24 | - |
dc.citation.title | The Korean journal of hepatology | - |
dc.citation.volume | 15 Suppl 6 | - |
dc.citation.startPage | S13 | - |
dc.citation.endPage | 24 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | hepatitis B surface antigen | - |
dc.subject.keywordPlus | hepatitis B vaccine | - |
dc.subject.keywordPlus | acute disease | - |
dc.subject.keywordPlus | epidemiology | - |
dc.subject.keywordPlus | hepatitis B | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | preventive health service | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | Acute Disease | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Hepatitis B | - |
dc.subject.keywordPlus | Hepatitis B Surface Antigens | - |
dc.subject.keywordPlus | Hepatitis B Vaccines | - |
dc.subject.keywordPlus | Hepatitis B, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Immunization Programs | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | Seroepidemiologic Studies | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.